Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Enveda, a Colorado-based biotech, has received a $20 million investment from French pharma major Sanofi. According to Enveda, ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Sanofi invests in Enveda, reaffirming the industry’s confidence in its AI drug discovery platform and ability to deliver differentiated medicines.

Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials: Boulder, Colorado Friday, February 28, 2025, 16:00 Hrs [IST] Enveda, a leading biotechnolog ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

While early-stage, the Adagene deal is another example of Sanofi's determination to bolster its R&D pipeline via a string of deals, including a $5.2 billion, strategic-level alliance with UK ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...